都市激情在线亚洲国产91_欧美日韩国产国语对白_av成人毛片在线免费观看_少妇爆乳无码专区网站_亚洲Aⅴ无码吞精久久AV_亚洲AV毛片一区无码日韩_国产成人精品1024视频网站_最新综艺节目国产精品喷浆_国产在线拍揄自揄视频网站_天天少妇被猛烈进入在线播放

3358288340
CN
CN EN
China's first infliximab biosimilar drug ready for export, Kexing Biopharm initiated drug registration in 17 countries

Release date:2021 - 07 - 29

Following the NMPA's approval for the marketing application of infliximab biosimilar (CMAB008) on July 14, Kexing Biopharm quickly started working on an overseas sales plan for the drug.


On July 23, a ceremony was held in Taizhou to confirm the first drug registration countries and hand over technical files for commercial cooperation of CMAB008 (infliximab) in the overseas market. The ceremony was held by Kexing Biopharm Co., Ltd. (hereinafter referred to as "Kexing Biopharm", stock code: 688136.SH) and Taizhou Mabtech Pharmaceutical Co., Ltd. (hereinafter referred to as "Taizhou Mabtech"), a wholly-owned subsidiary of Mabpharm Limited (hereinafter referred to as "Mabpharm", stock code: 2181.HK). Kexing Biopharm plans to initiate drug registration in 17 countries, including Brazil, India, Egypt and Indonesia, with some countries expected to start sales in the near future.


The signing ceremony was presided over by Li Yunfeng, ED & CFO of Mabpharm. Other attendees included the following: Wu Xiang, Secretary of Party Working Committee & Director of Management Committee, Jiang Peng, member of Party Working Committee & Deputy Director of Management Committee, Ju Bin, Director of Party and Government Office, Taizhou Medical New & Hi-tech Industrial Development Zone; General Manager Zhao Yanqing and Deputy General Manager Shao Ke of Kexing Biopharm; Wang Hao, Executive Director of Mabpharm; Tao Jing, Executive Director of Mabpharm & General Manager of Taizhou Mabtech.


CMAB008 (infliximab) is mainly used to treat ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis in adults, Crohn's disease, fistulizing Crohn's disease and psoriasis in adults and children over 6 years of age. According to data from Fierce Pharma's website, infliximab saw global sales worth $4,195 million in 2020, ranking top 20 in global drug sales.


CMAB008 (infliximab) was the first infliximab biosimilar drug approved for marketing in China, while also being Taizhou Mabtech's first marketed product. In Taizhou Mabtech search for partners to realize fast drug marketing in the global market, Kexing Biopharm is a perfect fit. Kexing Biopharm has been recognized in the industry in recent years for its business strength and results overseas, as its overseas sales network keeps expanding over the years, thanks to its active involvement in overseas market layout. CMAB008 is another antibody drug in the commercial stage introduced by Kexing Biopharm. With this strong cooperation, Kexing Biopharm can enrich its product pipeline and improve its market layout. Furthermore, thanks to years of international operation experience, Kexing Biopharm has matured and optimized its overseas commercialization, providing strong support to China-made, high-quality biologics for marketing and promotion in foreign countries, helping to serve patients worldwide.


一区二区三区囯产精品乱码不卡 | chinese老头黄al片 | 久久99精品久久久久久琪琪 | 亚洲精品123区在线观看 | 毛片一本大道久久a久久精品综合 | 日韩精品亚洲一区二区三区 | 国产精品内射久久久久欢欢 | 亚洲国产精品无码久久久久久曰 | 日产亚洲一卡2卡3卡4卡网站 | 色欲久久精品亚洲AV无码一区 | 内射无套在线观看高清完整免费 | 国产精品久久无码一区二. 精品国产髙清在线看国产毛片 | 精品国产青草久久久久福利 | 精品深夜AV无码一区二区老年 | 亚洲AV无一区二区三区 | 内射一面膜上边一面膜下边 | 亚洲国产精品人人爽夜夜爽 | 欧美亚洲精品中文字幕乱码免费高清 | 91人人人玩人人妻精品99 | 国产喷水1区2区3区咪咪爱AV | 成人VA在线一区二区三区四区 | 欧美极品欧美精品欧美视频 | 精品国产粉嫩内射白浆内射双马尾 | 久久91综合国产91久久精品 | 国产sanji高清在线视频观看 | 男生女生在床上插插插的免费动漫 | 久久影院午夜理论片无码 | 中文字幕亚洲综合久久菠萝蜜 | 综合激情区视频一区视频二区 | 草莓黄瓜蜜桃视频app下载 | 欧美日韩视频综合一区无弹窗 | 亚洲AV综合AV一区二区综合 | 免费无码又爽又刺激网站直播 | 一级毛片不卡片免费观看 | 2018国产精华国产精品 | 黑人玩弄极品人妻系列 | 中文字幕无码家庭乱欲 | 国产欧美日韩亚洲精品区 | 中文字幕人成乱码中文乱码 | 欧美日韩一级久久久久久免费看 | 国产精品高潮视亚洲乱码 |